Endocrine Abstracts

Introduction: Osilodrostat is a potent, oral inhibitor of 11β-hydroxylase, the enzyme that catalyses final step of cortisol biosynthesis. In a phase II study, 15/19 patients treated with osilodrostat met the primary endpoint (normal urinary free cortisol (UFC) at 22 weeks); osilodrostat was generally well tolerated. This phase III study aims to confirm the efficacy and long-term safety of osilodrostat.Patients and methods: Adults (18–75 years) ...

Background: Transsphenoidal tumour resection (TSS) is the first-line treatment for Cushing’s disease (CD). With an experienced neurosurgeon, immediate remission rates >80% are expected for patients with microadenomas (<10 mm).Aim: To report initial and long-term remission rates in a specialist centre, and to ascertain factors associated with disease recurrence after TSS.Methods: Patients with CD (n=101, 28M, 7...

Introduction: Cushing’s disease (CD) is a rare disorder caused by an ACTH-secreting pituitary adenoma. Transsphenoidal surgery (TSS) is the recommended first-line treatment. However, an equivocal or even normal preoperative MRI can preclude the surgical management and the outcome of these patients.Objectives: Evaluate the relationship between preoperative MRI and TSS efficacy in patients with CD.Methods: Retrospective cohort s...

Background: In a large 12-month Phase III study, pasireotide led to rapid and sustained decreases in UFC and provided clinical benefit in patients with Cushing’s disease. Here, we report data following an open-label, open-ended extension.Methods: 162 patients with persistent/recurrent or de novo Cushing’s disease were randomized in the core study. 58 patients with mean UFC≤ULN or clinical benefit at month 12 entered the extension...

Introduction: In vitro assessments of osilodrostat (LCI699), a potent oral inhibitor of 11β-hydroxylase suggested potential drug–drug interactions (DDIs) with cytochrome P450 (CYP) enzyme metabolism. This clinical study evaluated the effect of osilodrostat on the pharmacokinetics (PK) of CYP1A2, CYP2C19, CYP2D6, and CYP3A4 probe substrates, caffeine, omeprazole, dextromethorphan, and midazolam, respectively.Methods: A single-centre, op...

Context: Cushing’s syndrome (CS) is a rare endocrine disease, due to cortisol hypersecretion. CS patients have several comorbidities, often still present after biochemical cure. There are no specific nursing healthcare programs to address this disease and achieve improved health related quality of life (HRQoL). Thus, an educational nursing intervention in these patients, through the development and promotion of specific educational tools, appears to be justified.<p cl...

Objective: To estimate the outcome of neurosurgery in patients with Cushing’s disease (CD) with and without pituitary adenoma visualisation on MRI.Material and methods: Patients with confirmed CD (11.2008–11.2014) by both inferior petrosal sinus sampling (IPSS) and histological evaluation after neurosurgery were enrolled into the study. Subjects were referred for IPSS because of non-visualised pituitary adenoma or contradictory results of non-i...